Agrow's Complete Guide to Generic Pesticides: Volume 2, Products and Markets

Publication Date	January 2007
Publisher	Agrow
Product Type	Report
Pages	268
ISBN Number	not applicable
Product Code	AGR00003

Price

£750.00
approximately: $1,096 | €822

PDF

Order above formats by FAX

Summary

This report is the second in a set of three investigating the current state of the generic pesticide industry and market This first report contains profiles of 100 of the most important generic pesticide companies in the world today. The second report contains profiles of 100 of the most important generic pesticide ais. The third report provides a detailed analysis of the generic pesticide market and industry, and explores the forces that will drive the development of the generic pesticide industry over the next few years. These three reports are updated editions of reports on the generic pesticide industry that Agrow published first in 1998 and then, as new editions, in 2001 and 2005 Total global sales were the main criteria for inclusion of an ai in this report Other factors taken into account include the number of generic companies manufacturing each ai, usage figures, and how recently the ai lost its patent protection Each profile begins with a box detailing the activity and general uses for that specific ai. The profile then continues with: information on the registration status of the ai in major markets such as the US and the EU; details on the generic companies that currently manufacture the ai; and information on the size of the global market, both in terms of volume manufactured and sales value. Not all of these sections will appear in every ai profile An ai is included in this report, and therefore classified as generic, if it is being independently manufactured by companies that did not originally develop the ai or have not obtained production licenses from the original developer.

This means that certain newer ais have been included, such as thiamethoxam, even though they are still patent-protected in a large number of markets. If an ai is currently being manufactured by at least several generic producers, such as is the case with thiamethoxam, then it was considered for inclusion Of the 100 ais profiled in this report, 10 are new profiles not included in any previous edition: the fungicides epoxinconaole and kresoxim-methyl; the herbicides fenoxaprop-P-ethyl, glufosinate, nicosulfuron, pretilachlor and quizalofop; and the insecticides and acaricides emamectin, fipronil and thiamethoxam. Nine of these ais have only recently become "generic", either because they are beginning to lose their patent protection or because they are being produced by generic manufacturers based in countries where the ai is not protected. The exception is the herbicide glufosinate, which is rather older than the other ais and seems to have become more popular with generic manufacturers mainly because of the uptake of glufosinatetolerant GM crops in an increasing number of countries

Content

CHAPTER 1 OVERVIEW
- 1.1 Background to reports
- 1.2 Outline of Companies report
- 1.3 Outline of Products and Markets report
- 1.4 Outline of Business Strategies report
- 1.5 Information sources
- 1.6 Introduction to Products and Markets report
- 1.7 Registration status
- 1.8 Market profile
- 1.9 New entries
SECTION 1 FUNGICIDES
- CHAPTER 2 BENOMYL
  - 2.1 Registration status
  - 2.2 Market profile
  - 2.3 Future prospects
- CHAPTER 3 CAPTAN
  - 3.1 Registration status
  - 3.2 Market profile
  - 3.3 Future prospects
- CHAPTER 4 CARBENDAZIM
  - 4.1 Registration status
  - 4.2 Market profile
  - 4.3 Future prospects
- CHAPTER 5 CLOROTALONIL
  - 5.1 Registration status
  - 5.2 Market profile
  - 5.3 Future prospects
- CHAPTER 6 CYMOXANIL
  - 6.1 Registration status
  - 6.2 Market profile
  - 6.3 Future prospects
- CHAPTER 7 EPOXICONAZOLE
  - 7.1 Registration status
  - 7.2 Market profile
  - 7.3 Future prospects
- CHAPTER 8 FOSETYL-ALUMINIUM
  - 8.1 Registration status
  - 8.2 Market profile
  - 8.3 Future prospects
- CHAPTER 9 EXACONAZOLE
  - 9.1 Registration status
  - 9.2 Market profile
  - 9.3 Future prospects
- CHAPTER 10 KRESOXIM-METYL
  - 10.1 Registration status
  - 10.2 Market profile
  - 10.3 Future prospects
- CHAPTER 11 MANCOZEB
  - 11.1 Registration status
  - 11.2 Market profile
  - 11.3 Future prospects
- CHAPTER 12 MANEB
  - 12.1 Registration status
  - 12.2 Market profile
  - 12.3 Future prospects
- CHAPTER 13 METALAXYL
  - 13.1 Registration status
  - 13.2 Market profile
  - 13.3 Future prospects
- CHAPTER 14 MYCLOBUTANIL
  - 14.1 Registration status
  - 14.2 Market profile
  - 14.3 Future prospects
- CHAPTER 15 PROCLORAZ
  - 15.1 Registration status
  - 15.2 Market profile
  - 15.3 Future prospects
- CHAPTER 16 PROPAMOCARB
  - 16.1 Registration status
  - 16.2 Market profile
  - 16.3 Future prospects
- CHAPTER 17 PROPICONAZOLE
  - 17.1 Registration status
  - 17.2 Market profile
  - 17.3 Future prospects
- CHAPTER 18 TEBUCONAZOLE
  - 18.1 Registration status
  - 18.2 Market profile
  - 18.3 Future prospects
- CHAPTER 19 TIOPANATE-METYL
  - 19.1 Registration status
  - 19.2 Market profile
  - 19.3 Future prospects
- CHAPTER 20 TIRAM
  - 20.1 Registration status
  - 20.2 Market profile
  - 20.3 Future prospects
- CHAPTER 21 TRIADIMEFON
  - 21.1 Registration status
  - 21.2 Market profile
  - 21.3 Future prospects
- CHAPTER 22 ZIRAM
  - 22.1 Registration status
  - 22.2 Market profile
  - 22.3 Future prospects
SECTION 2 ERBICIDES
- CHAPTER 23 2,4-D
  - 23.1 Registration status
  - 23.2 Market profile
  - 23.3 Future prospects
- CHAPTER 24 ACETOCLOR
  - 24.1 Registration status
  - 24.2 Market profile
  - 24.3 Future prospects
- CHAPTER 25 ALACLOR
  - 25.1 Registration status
  - 25.2 Market profile
  - 25.3 Future prospects
- CHAPTER 26 AMETRYN
  - 26.1 Registration status
  - 26.2 Market profile
  - 26.3 Future prospects
- CHAPTER 27 ATRAZINE
  - 27.1 Registration status
  - 27.2 Market profile
  - 27.3 Future prospects
- CHAPTER 28 BENSULFURON-METYL
  - 28.1 Registration status
  - 28.2 Market profile
  - 28.3 Future prospects
- CHAPTER 29 BENTAZONE
  - 29.1 Registration status
  - 29.2 Market profile
  - 29.3 Future prospects
- CHAPTER 30 BROMOXYNIL
  - 30.1 Registration status
  - 30.2 Market profile
  - 30.3 Future prospects
- CHAPTER 31 BUTACLOR
  - 31.1 Registration status
  - 31.2 Market profile
  - 31.3 Future prospects
- CHAPTER 32 CLORSULFURON
  - 32.1 Registration status
  - 32.2 Market profile
  - 32.3 Future prospects
- CHAPTER 33 CLOMAZONE
  - 33.1 Registration status
  - 33.2 Market profile
  - 33.3 Future prospects
- CHAPTER 34 DICAMBA
  - 34.1 Registration status
  - 34.2 Market profile
  - 34.3 Future prospects
- CHAPTER 35 DICLOFOP-METYL
  - 35.1 Registration status
  - 35.2 Market profile
  - 35.3 Future prospects
- CHAPTER 36 DIURON
  - 36.1 Registration status
  - 36.2 Market profile
  - 36.3 Future prospects
- CHAPTER 37 FENOXAPROP-P-ETYL
  - 37.1 Registration status
  - 37.2 Market profile
  - 37.3 Future prospects
- CHAPTER 38 FLUOMETURON
  - 38.1 Registration status
  - 38.2 Market profile
  - 38.3 Future prospects
- CHAPTER 39 FLUROXYPYR
  - 39.1 Registration status
  - 39.2 Market profile
  - 39.3 Future prospects
- CHAPTER 40 GLUFOSINATE
  - 40.1 Registration status
  - 40.2 Market profile
  - 40.3 Future prospects
- CHAPTER 41 GLYPOSATE
  - 41.1 Registration status
  - 41.2 Market Profile
  - 41.3 Future prospects
- CHAPTER 42 IMAZETAPYR
  - 42.1 Registration status
  - 42.2 Market profile
  - 42.3 Future prospects
- CHAPTER 43 IOXYNIL
  - 43.1 Registration status
  - 43.2 Market profile
  - 43.3 Future prospects
- CHAPTER 44 ISOPROTURON
  - 44.1 Registration status
  - 44.2 Market profile
  - 44.3 Future prospects
- CHAPTER 45 LINURON
  - 45.1 Registration status
  - 45.2 Market profile
  - 45.3 Future prospects
- CHAPTER 46 MCPA
  - 46.1 Registration status
  - 46.2 Market profile
  - 46.3 Future prospects
- CHAPTER 47 METAMITRON
  - 47.1 Registration status
  - 47.2 Market profile
  - 47.3 Future prospects
- CHAPTER 48 METOLACLOR
  - 48.1 Registration status
  - 48.2 Market profile
  - 48.3 Future prospects
- CHAPTER 49 METRIBUZIN
  - 49.1 Registration status
  - 49.2 Market profile
  - 49.3 Future prospects
- CHAPTER 50 METSULFURON-METYL
  - 50.1 Registration status
  - 50.2 Market profile
  - 50.3 Future prospects
- CHAPTER 51 MOLINATE
  - 51.1 Registration status
  - 51.2 Market profile
  - 51.3 Future prospects
- CHAPTER 52 NICOSULFURON
  - 52.1 Registration status
  - 52.2 Market profile
  - 52.3 Future prospects
- CHAPTER 53 OXYFLUORFEN
  - 53.1 Registration status
  - 53.2 Market profile
  - 53.3 Future prospects
- CHAPTER 54 PARAQUAT
  - 54.1 Registration status
  - 54.2 Market profile
  - 54.3 Future prospects
- CHAPTER 55 PENDIMETALIN
  - 55.1 Registration status
- CHAPTER 50 METSULFURON-METYL
  - 50.1 Registration status
  - 50.2 Market profile
  - 50.3 Future prospects
- CHAPTER 51 MOLINATE
  - 51.1 Registration status
  - 51.2 Market profile
  - 51.3 Future prospects
- CHAPTER 52 NICOSULFURON
  - 52.1 Registration status
  - 52.2 Market profile
  - 52.3 Future prospects
- CHAPTER 53 OXYFLUORFEN
  - 53.1 Registration status
  - 53.2 Market profile
  - 53.3 Future prospects
- CHAPTER 54 PARAQUAT
  - 54.1 Registration status
  - 54.2 Market profile
  - 54.3 Future prospects
- CHAPTER 55 PENDIMETALIN
  - 55.1 Registration status
  - 55.2 Market profile
  - 55.3 Future prospects
- CHAPTER 56 PRETILACLOR
  - 56.1 Registration status
  - 56.2 Market profile
  - 56.3 Future prospects
- CHAPTER 57 PROMETRYN
  - 57.1 Registration status
  - 57.2 Market profile
  - 57.3 Future prospects
- CHAPTER 58 PROPANIL
  - 58.1 Registration status
  - 58.2 Market profile
  - 58.3 Future prospects
- CHAPTER 59 PYRAZOSULFURON-ETYL
  - 59.1 Registration status
  - 59.2 Market profile
  - 59.3 Future prospects
- CHAPTER 60 QUINCLORAC
  - 60.1 Registration status
  - 60.2 Market profile
  - 60.3 Future prospects
- CHAPTER 61 QUIZALOFOP-P
  - 61.1 Registration status
  - 61.2 Market profile
  - 61.3 Future prospects
- CHAPTER 62 SIMAZINE
  - 62.1 Registration status
  - 62.2 Market profile
  - 62.3 Future prospects
- CHAPTER 63 TRIFLURALIN
  - 63.1 Registration status
  - 63.2 Market profile
  - 63.3 Future prospects
SECTION 3 INSECTICIDES
- CHAPTER 64 ABAMECTIN
  - 64.1 Registration status
  - 64.2 Market profile
  - 64.3 Future prospects
- CHAPTER 65 ACEPATE
  - 65.1 Registration status
  - 65.2 Market profile
  - 65.3 Future prospect
- CHAPTER 66 ACETAMIPRID
  - 66.1 Registration status
  - 66.2 Market profile
  - 66.3 Future prospects
  - APTER 67 AMITRAZ
  - 67.1 Registration status
  - 67.2 Market profile
  - 67.3 Future prospects
- CHAPTER 68 BIFENTRIN
  - 68.1 Registration status
  - 68.2 Market profile
  - 68.3 Future prospects
- CHAPTER 69 BUPROFEZIN
  - 69.1 Registration status
  - 69.2 Market profile
  - 69.3 Future prospects
- CHAPTER 70 CARBOFURAN
  - 70.1 Registration status
  - 70.2 Market profile
  - 70.3 Future prospects
- CHAPTER 71 CARBOSULFAN
  - 71.1 Registration status
  - 71.2 Market profile
  - 71.3 Future prospects
- CHAPTER 72 CLORPYRIFOS
  - 72.1 Registration status
  - 72.2 Market profile
  - 72.3 Future prospects
- CHAPTER 73 CYFLUTRIN
  - 73.1 Registration status
  - 73.2 Market profile
  - 73.3 Future prospects
- CHAPTER 74 CYEXATIN
  - 74.1 Registration status
  - 74.2 Market profile
.3 Future prospects
CHAPTER 75 CYPERMETRIN (AND ALPA-CYPERMETRIN)
- 75.1 Registration status
- 75.2 Market profile
- 75.3 Future prospects
- CHAPTER 76 DELTAMETRIN
  - 76.1 Registration status
  - 76.2 Market profile
  - 76.3 Future prospects
- CHAPTER 77 DICLORVOS
  - 77.1 Registration status
  - 77.2 Market profile
  - 77.3 Future prospects
- CHAPTER 78 DICOFOL
  - 78.1 Registration status
  - 78.2 Market profile
  - 78.3 Future prospects
- CHAPTER 79 DIMETOATE
  - 79.1 Registration status
  - 79.2 Market profile
  - 79.3 Future prospects
- CHAPTER 80 EMAMECTIN
  - 80.1 Registration status
  - 80.2 Market profile
  - 80.3 Future prospects
- CHAPTER 81 ENDOSULFAN
  - 81.1 Registration status
  - 81.2 Market Profile
  - 81.3 Future prospects
- CHAPTER 82 ETION
  - 82.1 Registration Status
  - 82.2 Market Profile
  - 82.3 Future prospects
- CHAPTER 83 FENTION
  - 83.1 Registration status
  - 83.2 Market profile
  - 83.3 Future prospects
- CHAPTER 84 FIPRONIL
  - 84.1 Registration status
  - 84.2 Market profile
  - 84.3 Future prospects
- CHAPTER 85 IMIDACLOPRID
  - 85.1 Registration status
  - 85.2 Market profile
  - 85.3 Future prospects
- CHAPTER 86 LAMBDA-CYALOTRIN
  - 86.1 Registration status
  - 86.2 Market profile
  - 86.3 Future prospects
- CHAPTER 87 MALATION
  - 87.1 Registration status
  - 87.2 Market profile
  - 87.3 Future prospects
- CHAPTER 88 METAMIDOPOS
  - 88.1 Registration status
  - 88.2 Market profile
  - 88.3 Future prospects
- CHAPTER 89 METOMYL
  - 89.1 Registration status
  - 89.2 Market profile
  - 89.3 Future prospects
- CHAPTER 90 MONOCROTOPOS
  - 90.1 Registration status
  - 90.2 Market profile
  - 90.3 Future prospects
- CHAPTER 91 PARATION-METYL
  - 91.1 Registration status
  - 91.2 Market profile
  - 91.3 Future prospects
- CHAPTER 92 PERMETRIN
  - 92.1 Registration status
  - 92.2 Market profile
  - 92.3 Future prospects
- CHAPTER 93 PORATE
  - 93.1 Registration status
  - 93.2 Market profile
  - 93.3 Future prospects
- CHAPTER 94 POSPAMIDON
  - 94.1 Registration status
  - 94.2 Market profile
  - 94.3 Future prospects
- CHAPTER 95 PROFENOFOS
  - 95.1 Registration status
  - 95.2 Market profile
  - 95.3 Future prospects
- CHAPTER 96 PROPARGITE
  - 96.1 Registration status
  - 96.2 Market profile
  - 96.3 Future prospects
- CHAPTER 97 PYRIDABEN
  - 97.1 Registration status
  - 97.2 Market profile
  - 97.3 Future prospects
- CHAPTER 98 QUINALPOS
  - 98.1 Registration status
  - 98.2 Market profile
  - 98.3 Future prospects
- CHAPTER 99 TERBUFOS
  - 99.1 Registration status
  - 99.2 Market profile
  - 99.3 Future prospects
- CHAPTER 100 TIAMETOXAM
  - 100.1 Registration status
  - 100.2 Market profile
  - 100.3 Future prospects
- CHAPTER 101 TRICLORFON
  - 101.1 Registration status
  - 101.2 Market profile
  - 101.3 Future prospects